HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
CAMBRIDGE, Mass., Aug. 15, 2017 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Hugh Cole has been appointed as chief business officer and head of corporate development. He brings over 25 years of experience in biotech across business development, corporate strategy, R&D portfolio, program, and alliance management, commercial planning and execution, and overall corporate leadership.
Most recently he served as chief business officer for ARIAD Pharmaceuticals, where in under three years, he led nine business development transactions for the company and helped develop and implement ARIAD's new corporate strategy.
“Hugh has tremendous experience and a great track record in the pharmaceutical and biotechnology industries, with robust knowledge of oncology pipeline progression and commercial strategy. We are thrilled to welcome him to Jounce at a critical point in our drug development process,” said Richard Murray, Ph.D., chief executive officer of Jounce Therapeutics. “As we continue with the clinical development of our lead program, JTX-2011, and progress our pipeline of innovative immunotherapies, it will be crucial to have Hugh’s business and strategic leadership, and portfolio management expertise.”
In addition to his former role at ARIAD, Mr. Cole was the former senior vice president, strategic planning and program management at Shire plc, where he oversaw the company’s portfolio management and rare disease strategic planning processes. At Shire, Mr. Cole was also globally responsible for the development strategy and commercialization of the rare disease drug Firazyr®, and led several important transactions for the company. Prior to joining Shire, Mr. Cole was vice president, corporate development for Oscient Pharmaceuticals and served as senior director, business development and strategy at Millennium Pharmaceuticals. Earlier in his career, Mr. Cole worked as a management consultant for The Wilkerson Group, a leading consultancy focused on life science companies and, prior to that, as an investment analyst for Fred Alger Management, where he covered the biotechnology and pharmaceutical industries. He earned his Masters of Business Administration in health care management and finance at the Wharton School and his Bachelor of Arts in chemistry from Harvard University.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 2 trial. For more information, please visit www.jouncetx.com/.
Media Contact: Katie Engleman Pure Communications, Inc. (910) 509-3977 [email protected] Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
